Deschloroetizolam
Viewing r1 — May 9, 2026 — CURRENT
Back to HistoryInteractions, related substances, and reports reflect the current entry and are not shown for historical revisions.
Deschloroetizolam — also known as etizolam-2 — is a synthetic depressant of the thienotriazolodiazepine class. It is the dechlorinated structural analog of Etizolam, measurably weaker than its parent compound.[1] It amplifies the brain's main inhibitory signal (GABA), slowing neuronal activity throughout the central nervous system.[2]
Psychedex is in open beta. We are still fine-tuning the generation and review process. Please double-check sources.
benzodiazepines, thienodiazepines, Z-drugs (partial) +2 morebenzodiazepines, thienodiazepines, Z-drugs (partial), barbiturates (partial), alcohol (partial) show less
The thienotriazolodiazepine scaffold was patented in 1975 by Yoshitomi Pharmaceutical, but deschloroetizolam was never developed as a medicine.[3] It appeared in UK drug markets in 2014, part of a wave of designer benzodiazepines created as scheduling pressure tightened on traditional options.[4] It remains unscheduled in most countries, though etizolam's 2026 US Schedule I placement strengthens the case for prosecuting it as an analog.
Subjective effects include sedation, anxiety relief, muscle relaxation, mild euphoria, and cognitive slowing. The experience is a slow-settling, diffuse calm — less sharp and less rewarding than etizolam, placing it among the mildest designer benzodiazepines.[1] Characteristic unwanted effects include delusions of sobriety, compulsive redosing, and dose-dependent memory gaps.
Deschloroetizolam produces high abuse liability — physical dependence develops within days, and stopping abruptly after regular use risks life-threatening seizures.[5] The greatest acute danger is combining it with opioids, alcohol, or other depressants, which can shut down breathing — the mechanism behind nearly all designer benzodiazepine deaths.[6] No formal human studies exist; understanding rests on a single exposure case, lab metabolite work, and analogy to etizolam.[7]
History[edit]
Discovery
The thienotriazolodiazepine chemical family was first patented in 1975 by researchers at Yoshitomi Pharmaceutical in Japan.[3] From that work, etizolam — the version with a chlorine atom on the phenyl ring — was selected for clinical development and approved in Japan by 1983.[6] Deschloroetizolam, missing that single chlorine atom,[8] was never considered for pharmaceutical use.
Market emergence
Deschloroetizolam appeared in UK drug markets in 2014,[4] part of a broad wave of designer benzodiazepines filling the gap left by tightening controls on traditional options.[9] By late 2015 it was confirmed on research chemical markets,[10] and Swedish authorities documented at least one acute intoxication case between 2012 and 2016.[11]
Modern status
Its relatively low potency — ranking at the bottom of comparative analyses alongside metizolam and nifoxipam[1] — has limited its commercial appeal relative to more potent compounds. It appears rarely in severe intoxication reports and remains a minor presence in designer benzodiazepine markets.[12]
The name follows standard chemical convention: "deschloro-" marks the removal of a chlorine atom from the parent compound Etizolam. The alternate name "Etizolam-2" reflects its position as a structural derivative. Neither name carries street-level recognition — the compound circulates primarily under its chemical designation in research chemical markets.
Chemistry[edit]
Structural class
Deschloroetizolam belongs to the thienotriazolodiazepine class — a family built from three fused rings: a thiophene ring, a diazepine ring, and a triazole ring.[8][4] Forensic toxicology consistently uses the full name "thienotriazolodiazepine" to distinguish this family from simpler thienodiazepines.[13]
Structure-activity relationship
Deschloroetizolam differs from etizolam by a single missing chlorine atom on the phenyl ring.[8] That chlorine contributes to tighter receptor binding in etizolam — removing it produces a measurably weaker compound.[1] Its molecular formula is C₁₇H₁₆N₄S (molecular weight 308.4 g/mol).
Pharmacology[edit]
Mechanism of action
Deschloroetizolam enhances the effect of GABA — the brain's main inhibitory signal — by binding to GABA-A receptors and amplifying their response.[2] This reduces neuronal excitability broadly, producing sedation, anxiety relief, muscle relaxation, and memory suppression depending on which brain circuits are engaged.[2]
Pharmacokinetics
Human data are extremely limited — the only controlled exposure measured saliva concentrations after a single 6 mg oral dose.[7] Peak concentration occurred around 30 minutes after ingestion, with traces detectable through the 18-hour observation window. Elimination half-life and most other pharmacokinetic parameters remain uncharacterized.[6][14]
Metabolism
Lab studies identified at least two hydroxylated breakdown products.[8] By structural analogy to etizolam, the main metabolizing enzymes are likely CYP2C19 and CYP3A4. People who genetically metabolize CYP2C19 substrates slowly can have several times higher drug exposure — and adding a CYP3A4-blocking drug can amplify this further.[15] inferred
Neuroscience[edit]
Where it acts
Deschloroetizolam boosts inhibitory GABA signaling across the brain, reducing neuronal excitability throughout the central nervous system.[2] Slowed cortical activity produces sedation and cognitive impairment; reduced amygdala reactivity produces anxiety relief; quieted motor circuits produce muscle relaxation.[2]
Tolerance and adaptation
With repeated use, the brain reduces the number of GABA receptors available — particularly those driving sedation.[16] This happens within days. Simultaneously, excitatory glutamate signaling increases to compensate.[5]
The result is less inhibition and more excitation. This explains both rising tolerance and why stopping suddenly can cause seizures — the brain has become dependent on the drug to maintain balance.
Key unknowns include whether deschloroetizolam's hydroxylated metabolites[8] remain active at the receptor, and whether its receptor subunit preferences match what is observed with classical benzodiazepines. No neuroimaging or electrophysiology studies have been conducted with this compound.
Subjective Effects[edit]
Deschloroetizolam settles in gradually — a diffuse, low-level calm that loosens muscles and dims anxious background noise. At lower doses the experience is subtle enough to mistake for simply feeling relaxed. At higher doses, thinking slows noticeably, coordination falters, and memory gaps appear that the user may not notice happening.
Relative to etizolam, the experience is weaker — less euphoria, softer anxiety relief, less amnesia per milligram.[1] Among designer benzodiazepines, it sits at the low-potency end alongside metizolam and nifoxipam, closer in character to a mild prescription benzodiazepine than to intensely sedating compounds like flubromazolam or clonazolam.[12]
Effect Grid
Clear anxiety suppression, moderate sedation, and definite muscle relaxation define the 4–6 mg range. The Ameline et al. 2018 self-experiment at 6 mg — the only controlled human exposure — produced tiredness, dizziness, difficulty speaking, and concentration problems, placing this dose at the upper boundary of the common tier.
Emotional suppression becomes noticeable: affective responses are dampened, and stressors that would normally provoke anxiety feel distant. Disinhibition and delusions of sobriety become relevant safety concerns. Anterograde amnesia risk increases. Driving and complex cognitive tasks are unsafe at this level.
Modeled from the effect's dose-dependence curve — not per-substance measurements.
Sleep-transition hallucinations
Dizziness · Bodily heaviness · Body high · Breathing alteration · Headache · Nystagmus (eye wobbles) · Dry mouth · Nausea
Headache · Nystagmus (eye wobbles) · Dry mouth · Nausea
Cognitive fatigue · Information processing suppression · Focus suppression · Memory suppression · Language suppression · Memory fragmentation · Suggestibility enhancement · Compulsive redosing urge · Cognitive euphoria · Confusion · Thought disorganization · Amnesia
Memory suppression · Language suppression · Memory fragmentation · Compulsive redosing urge · Cognitive euphoria · Confusion · Thought disorganization · Amnesia
Timeline
Initial anxiolysis and subtle relaxation emerge. A faint softening of tension is perceptible but effects remain subclinical.
Progressive sedation and muscle relaxation build steadily toward full effect. Cognitive slowing becomes apparent.
Maximum sedation, anxiolysis, cognitive impairment, and disinhibition. Delusions of sobriety are most prominent. Amnesia risk is highest.
Gradual reduction of sedation. Residual cognitive impairment and motor coordination effects persist beyond subjective awareness of intoxication.
Lingering drowsiness, possible rebound anxiety, and residual cognitive dulling.
⚠ Do not drive or operate machinery for at least 12 hours after ingestion — residual impairment may persist beyond subjective effect offset.
Safety[edit]
- Acute toxicity
- Low
- Chronic toxicity
- Moderate
- Withdrawal
- Life-threateningfatal risk
- Tolerance buildup
- rapid
- Tolerance reset
- 10.5 days
- Physical
- High
- Psychological
- High
- Compulsive redosing
- Moderate
- Dose escalation
- High
- Cross-tol.
- benzodiazepines · thienodiazepines · Z-drugs (partial)
Toxicity
Acute toxicity
No toxicity data exist for deschloroetizolam — no lethal dose, no safety margin. Taken alone, the compound appears to have low acute toxicity: no deaths attributable to it alone have been published.[12] One confirmed intoxication case recovered with flumazenil,[11] and one additional detection was reported from an acute intoxication without published clinical details.[17]
Polydrug lethality
The primary lethality risk is synergistic respiratory depression — combining deschloroetizolam with opioids, alcohol, other benzodiazepines, or GHB. Nearly all designer benzodiazepine deaths occur in polydrug combinations.[6]
Illicitly obtained benzodiazepines have been found to contain opioid adulterants, creating unintentional polydrug exposure with potentially fatal respiratory depression.[18]
Psychological risks
- Disinhibition: impaired judgment at higher doses, with risk of actions the user would not undertake sober
- Delusions of sobriety: users may believe they are less impaired than they are, promoting redosing and dangerous behavior
- Compulsive redosing: anxiolysis, disinhibition, and amnesia combine so users redose without recalling previous doses
- Amnesia: dose-dependent memory gaps, less pronounced than with flubromazolam or clonazolam[1] but significant at strong doses
- Rebound anxiety: anxiety exceeding baseline during offset and for days after use, reinforcing continued use[5]
Prolonged regular use carries risk of depressive symptoms, emotional suppression, and cognitive impairment persisting into the withdrawal period.[13]
Tolerance and dependence
Tolerance to sedation develops within days. Physical dependence builds with regular use — stopping abruptly triggers the full benzodiazepine withdrawal syndrome: rebound effect anxiety, insomnia, tremor, and life-threatening seizures in severe cases.[5] Gradual tapering with a long-acting benzodiazepine such as diazepam is the standard approach.
The brain compensates for chronic exposure by reducing GABA receptor sensitivity[16] and ramping up excitatory glutamate signaling.[5] Psychological dependence is reinforced by the anxiolytic effect — rebound anxiety motivates continued dosing.[13] Cross-tolerance exists with all benzodiazepines, barbiturates, alcohol, and Z-drugs.
Drug interactions
All interaction data are inferred from class-level evidence — no substance-specific interaction studies exist.
The most dangerous combination is opioids. GABA enhancement and opioid receptor activation both suppress breathing through separate brainstem pathways — together they account for the majority of benzodiazepine-involved deaths.[6][18] Alcohol, other benzodiazepines, barbiturates, GHB/GBL, and Z-drugs all add sedation through the same receptor. Drugs that block CYP3A4 or CYP2C19 — certain antifungals, antibiotics, and proton pump inhibitors — can push blood levels several times higher than expected.[15] Stimulants mask sedation without reducing respiratory depression, encouraging redosing while the danger persists. inferred
Contraindications
No substance-specific contraindication data exist — the following are inferred from the benzodiazepine class:
Absolute contraindications:
- Concurrent use of opioids, alcohol, or other CNS depressants
- Known allergy to thienotriazolodiazepines or benzodiazepines
- Severe respiratory disease — GABA-A enhancement suppresses the drive to breathe
- Acute narrow-angle glaucoma citation needed
Relative contraindications:
- Genetic CYP2C19 poor metabolizer status — expected elevated blood levels and prolonged effects[15] inferred
- Concurrent CYP3A4 inhibitor therapy
- Myasthenia gravis
- Obstructive sleep apnea
- History of substance use disorder
- Pregnancy citation needed
- Liver impairment — reduced metabolic clearance expected
Harm Reduction[edit]
Forms & Identification
Deschloroetizolam has no pharmaceutical formulations — every sample originates from unregulated synthesis, with no guarantee of purity, identity, or dose accuracy.
Designer benzodiazepines are active at milligram-level doses and visually indistinguishable from each other as powders or pressed tablets. A sample sold as deschloroetizolam could contain flubromazolam or clonazolam — far more potent compounds with dramatically different risk profiles.
Reagent testing cannot reliably distinguish between designer benzodiazepines. Forensic-grade analysis (GC-MS or LC-MS) is the only reliable method for confirming identity. Drug checking services, where available, are the most accessible route to verification.
Guidelines
- Start with the lowest dose in the threshold range and wait at least 90 minutes before considering redosing — onset can be delayed
- Measure doses with a milligram-precision scale; volumetric dosing from a prepared solution is more accurate than weighing small amounts of powder
- Pre-measure the total intended dose and store remaining material out of reach before dosing — compulsive redosing under the influence is a well-documented pattern with this class
- Do not combine with opioids, alcohol, GHB, or other depressants under any circumstances
- Do not drive or operate machinery; impairment outlasts subjective effects
- Avoid consecutive-day dosing — physical dependence with benzodiazepines can develop within days of regular use
- Inform someone trusted about what was taken, when, and how much
Set & Setting
The anxiolytic and disinhibitory effects are strongly context-dependent. Using in unfamiliar or high-stakes environments increases the risk of impaired judgment leading to harmful decisions.
Delusions of sobriety are a defining feature of benzodiazepine intoxication — the user's own assessment of impairment is unreliable. A sober companion present can recognize compulsive redosing before it escalates.
Aftercare & integration. Benzodiazepine aftercare centers on managing rebound effects. Anxiety, insomnia, and irritability commonly intensify for one to several days after a single use — and these symptoms can motivate further dosing if not anticipated.
Prioritize sleep hygiene, hydration, and light activity in the days following use. Do not use other depressants — including alcohol — to manage rebound symptoms, as this extends the cycle of GABAergic disruption. If rebound anxiety is severe or persistent, consult a healthcare provider rather than self-medicating.
Recovery & Support
Benzodiazepine dependence is a medical condition requiring supervised management. Abrupt cessation after regular use risks life-threatening seizures — tapering under medical guidance is essential.
Standard clinical practice involves switching to a long-acting benzodiazepine, typically diazepam, and reducing the dose gradually over weeks to months. The Ashton Manual remains the most widely referenced tapering guide for benzodiazepine withdrawal.
Support resources include the SAMHSA National Helpline (1-800-662-4357, US), Benzo Buddies peer support community, and local addiction medicine services. Cognitive behavioral therapy has demonstrated efficacy for benzodiazepine discontinuation when combined with a medical taper.
Recovery resources, crisis lines, and support pathways → View all
Emergency Response
Recognizing an emergency:
- Breathing becomes slow, shallow, or stops
- Skin or lips turn blue or grey
- Person is unresponsive or cannot be woken
- Seizure activity (jerking movements, loss of consciousness)
These signs distinguish a medical emergency from expected sedation. Heavy drowsiness alone, while concerning, is not the same as respiratory failure.
Immediate steps:
- 1. Call emergency services immediately if breathing is compromised or the person is unresponsive
- 2. Place the person in the recovery position (on their side) to prevent choking if they vomit
- 3. Monitor breathing continuously until help arrives
- 4. Do not induce vomiting
- 5. Do not leave the person alone
What to tell the dispatcher:
- "They took a benzodiazepine-type substance" — name the compound if known
- Approximate amount and time of ingestion
- Any other substances taken (alcohol, opioids)
- Current symptoms: breathing rate, responsiveness, skin color
Good Samaritan laws in many jurisdictions protect people who call for help during a drug-related emergency.
Reversal agent: Flumazenil can reverse benzodiazepine effects and was used successfully in at least one documented deschloroetizolam intoxication.[11] It is hospital-administered, can precipitate seizures in dependent individuals, and is not available over the counter.
Legal Status[edit]
Deschloroetizolam's legal status is ambiguous internationally — not specifically scheduled in most countries, but increasingly subject to structural analog-act provisions following etizolam's 2026 US Schedule I placement.[19]
| Jurisdiction | Classification | Key provisions |
|---|---|---|
| United States (federal) | Not specifically scheduled | Not included in the April 2026 Schedule I placement of five designer benzodiazepines.[19] Likely subject to prosecution under the Federal Analogue Act (21 U.S.C. § 813) when intended for human consumption, given structural and pharmacological similarity to now-Schedule I etizolam. |
| United States (Alabama) | Schedule I | State-level scheduling effective July 15, 2024.citation needed |
| United Kingdom | Controlled (Psychoactive Substances Act 2016) | Illegal to produce, supply, or import for human consumption since May 26, 2016.[20] |
| Germany | Controlled (NpSG) | Specifically scheduled under the Neue-psychoaktive-Stoffe-Gesetz as of July 18, 2019; broader NpSG framework in force since November 26, 2016.citation needed |
| Sweden | Hazardous substance (hälsofarlig vara) | Classified since October 15, 2015 — one of the earliest national controls for deschloroetizolam.[20] |
| Russia | Schedule III | Controlled since 2017.citation needed |
| Switzerland | Nationally controlled | Controlled alongside other benzodiazepine derivatives since approximately April 2017.citation needed |
| Canada | Not scheduled | Not listed under the Controlled Drugs and Substances Act. Sale for human consumption without regulatory approval violates the Food and Drugs Act. |
| Australia | Unclear | Etizolam is Schedule 4. Analog provisions may apply to deschloroetizolam, but specific scheduling has not been confirmed by primary sources.citation needed |
Analog act considerations
The US Federal Analogue Act treats substances substantially similar in structure and pharmacology to a Schedule I or II drug as controlled when intended for human consumption. Deschloroetizolam differs from now-Schedule I etizolam by a single chlorine atom and shares the same mechanism of action — meeting the structural similarity threshold for analog-act prosecution. This creates a practical federal prohibition without specific scheduling.
Legal status changes frequently and varies by jurisdiction. This information is not legal advice — verify current status through authoritative sources before any activity.
references
- [1]
- [2]
- [3]
- [4]
- [5]
- [6]